RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis ...Middle East

With this approval, RINVOQ® (upadacitinib 15 mg, once daily) is the first and only Janus Kinase (JAK) inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the European Union (EU)1 Approval is supported by data from...

Hence then, the article about rinvoq upadacitinib approved by european commission as an oral treatment for adults with active non radiographic axial spondyloarthritis was published today ( Friday 29/07/2022 - 09:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis )

Also on site :

• Saudi Arabia to unify LPG gas cylinder prices nationwide from January 2026
• Two dozen killed in Ukrainian strike on Russian New Year’s celebration – governor
• Volunteer in Iran’s Revolutionary Guard reportedly killed during widening protests